Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia granted 163,100 inducement RSUs to 41 new hires under its 2024 Inducement Plan, with three-year time-based vesting.

Rhea-AI Summary

Intellia Therapeutics (NTLA) reported that on September 1, 2026 it granted inducement equity awards to 41 new employees under its 2024 Inducement Plan, as amended.

The awards consist of time-based restricted stock units covering an aggregate of 163,100 shares of common stock. One-third of each RSU award will vest annually over three years, subject to continued service with Intellia through each vesting date. These grants were made outside the stockholder-approved equity plans under the 2024 Inducement Plan, which was initially adopted by the board in June 2024, and were approved by the compensation committee as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Market Context

NTLA's prior close was $12.68 before this announcement. Against that baseline, the grant disclosure ...

Analysis

NTLA's prior close was $12.68 before this announcement. Against that baseline, the grant disclosure adds employee-compensation context rather than operating results. Investors can monitor future equity usage, insider activity, and the vesting schedule.

Key Figures

New employees: 41 employees Restricted stock units: 163,100 shares Annual vesting: One-third +3 more

6 metrics

New employees 41 employees Inducement grants awarded September 1, 2026

Restricted stock units 163,100 shares Aggregate RSUs granted under the 2024 Inducement Plan

Annual vesting One-third RSUs vesting annually

Vesting period Three years Time-based RSU vesting schedule

Award date September 1, 2026 Date inducement grants were awarded

Plan adoption June 2024 Board adoption of the 2024 Inducement Plan

Historical Context

5 past events · Latest: Aug 07 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 07	Inducement grants	Neutral	+0.7%	Grants to eight employees covering 38,200 restricted stock units
Aug 06	Quarterly earnings	Positive	+2.5%	Phase 3 HAELO data and second-quarter financial results
Jul 30	Earnings call notice	Neutral	+2.7%	Conference call scheduled for second-quarter results discussion
Jul 06	Inducement grants	Neutral	-2.3%	Grants to thirteen employees covering 53,250 common shares
Jun 05	Inducement grants	Neutral	-0.4%	Grants to six employees covering 47,150 common shares

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Comparable inducement-grant announcements produced mixed directional reactions, with no consistent response pattern.

Key Terms

restricted stock units, vesting, nasdaq listing rule 5635(c)(4), crispr gene editing

4 terms

restricted stock units financial

"The inducement grants consisted of time-based restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting financial

"with one-third of such RSUs vesting annually over three years"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

crispr gene editing technical

"focused on revolutionizing medicine leveraging CRISPR gene editing"

CRISPR gene editing is a laboratory technique that uses a guided molecular “scissor” to change DNA at specific locations, allowing scientists to add, remove, or correct genetic code. For investors, it matters because it underpins a new class of therapies and biotech products with high upside if they work, but also carries long development timelines, regulatory uncertainty, and technical risks that can create large swings in company value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on September 1, 2026, it awarded inducement grants to 41 new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 163,100 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.

All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, as amended, which was initially adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).

About Intellia Therapeutics

Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicomms.com

FAQ

What did Intellia Therapeutics (NTLA) announce regarding inducement grants in September 2026?

Intellia Therapeutics announced that on September 1, 2026 it granted inducement equity awards to 41 new employees under its 2024 Inducement Plan, as amended, as a material inducement to their employment.

How many Intellia Therapeutics (NTLA) shares are covered by the new inducement RSU grants?

The inducement grants consist of time-based restricted stock units for an aggregate of 163,100 shares of Intellia Therapeutics common stock, awarded to 41 newly hired employees.

What is the vesting schedule for the new Intellia Therapeutics (NTLA) inducement RSUs?

One-third of the restricted stock units granted as inducement awards will vest annually over three years, with all vesting subject to each recipient’s continued service with Intellia through the relevant vesting dates.

Under which plan and Nasdaq rule were Intellia Therapeutics (NTLA) inducement grants made?

The inducement awards were granted under Intellia’s 2024 Inducement Plan, as amended, outside its stockholder-approved equity plans, and were approved as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Who approved the latest Intellia Therapeutics (NTLA) inducement equity awards?

The inducement equity awards granted under the 2024 Inducement Plan were approved by Intellia’s compensation committee as material inducements to the new employees entering into employment with the company.